Company / Capital Returned to Shareholders per Share
Jazz Pharmaceuticals Capital Returned to Shareholders per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders per Share
$2.06
FY2025
5-year range
$2.06 / $5.37
FY2021-FY2025
Trend
-58.8%
vs FY2024
Sector context
#15 of 51
Health Care
What the data says
At $2.06, Jazz Pharmaceuticals's capital returned to shareholders per share ranks #15 of 51 in the Health Care sector. Capital Returned to Shareholders per Share has fluctuated over the past 10 years, ranging from $0.69 in FY2016 to $9.33 in FY2020.
Based on SEC 10-K filings.
2.06 in FY2025 with a 5-year CAGR of -26.1%.
Declined from $4.27 to $2.06 over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders per Share over time
Growth rates
- 3-Year CAGR
- -4.6%
- 5-Year CAGR
- -26.1%
- 10-Year CAGR
- -
Sector benchmark
-24.6% below sector average
Key checks
Key Insights
- In FY2025, capital returned to shareholders per share decreased 58.8% year-over-year.
- Ranks #15 out of 51 companies in the Health Care sector.
- Peak capital returned to shareholders per share was recorded in FY2020.
- Lowest capital returned to shareholders per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to Shareholders per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.06 | -58.8% |
| FY2024 | $5.00 | +17.2% |
| FY2023 | $4.27 | +79.5% |
| FY2022 | $2.38 | -55.7% |
| FY2021 | $5.37 | -42.5% |
| FY2020 | $9.33 | +444.8% |
| FY2019 | $1.71 | -63.8% |
| FY2018 | $4.73 | +186.1% |
| FY2017 | $1.65 | +139.8% |
| FY2016 | $0.69 | -32.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026